Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia

Indian Journal of Psychiatry

Volumn 52, Issue 2, 2010, Pages 100-105

  Shrivastava, Amresh K ^a,b   Johnston, Megan E ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Early Psychosis Program   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DONEPEZIL; HALOPERIDOL; NERVE GROWTH FACTOR; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANXIETY; ATTENTION; BRAIN DYSFUNCTION; COGNITION; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISABILITY; DISEASE COURSE; EDITORIAL; EPIDEMIOLOGY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETICS; HIPPOCAMPUS; HUMAN; LANGUAGE; LEARNING; LIMBIC SYSTEM; MEMORY; MENTAL DISEASE; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROBIOLOGY; NEUROIMAGING; NEUROPROTECTION; NEUROSCIENCE; NONHUMAN; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PREFRONTAL CORTEX; PSYCHOPHARMACOLOGY; PSYCHOSIS; PUBLIC HEALTH; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL ADAPTATION; SYMPTOMATOLOGY; THALAMUS; TREATMENT DURATION; VERBAL MEMORY; WORKING MEMORY;

EID: 77954492493     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.64575     Document Type: Editorial

References (37)

1. World Health Organization: World Health Report 2001, New Understanding New Hope, WHO Geneva.
2. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-1416
3. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": What we know in 2008 Part 3: neurobiology. Schizophr Res 2008;106:89-107.
4. Barch DM, Keefe RS. Anticipating DSM-V: Opportunities and challenges for cognition and psychosis. Schizophr Bull 2010;36:43-47
5. Buchanan RW, Koeppl P, Breier A. Stability of neurological signs with clozapine treatment. Biol Psychiatry 1994;36:198-200.
6. Bowie CR, Harvey PD. Cognition in schizophrenia: Impairments, determinants, and functional importance. Psychiatr Clin North Am 2005;28:613-33, 626.
7. Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B. Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS). Encephale 2008;34:557-562
8. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the" right stuff"? Schizophr Bull 2000;26:119-136
9. Herbener ES, Hill SK, Marvin RW, Sweeney JA. Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia. Am J Psychiatry 2005;162:1746-1748
10. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-472
11. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006;163:418-425
12. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55:82-87
13. Bell M, Tsang HW, Greig TC, Bryson GJ. Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia. Schizophr Bull 2009;35:738-747
14. Barch DM. The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol 2005;1:321-353
15. Kraus MS, Keefe RS. Cognition as an outcome in schizophrenia. Br J Psychiatry 2007;50:S46-51.
16. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-131
17. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009;11:663-671
18. Shrivastava A, Karnik S, Rao S. Re-examining cognition in schizophrenia. Indian J Psychiatry 1995;37:27.
19. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. Social cognition in schizophrenia: Recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull 2005;31:882-887
20. Andrews J, Wang L, Csernansky JG, Gado MH, Barch DM. Abnormalities of thalamic activation and cognition in schizophrenia. Am J Psychiatry 2006;163:463-469
21. Arnold SE. Cognition and neuropathology in schizophrenia. Acta Psychiatr Scand Suppl 1999;395:41-50.
22. Eack SM, E Mermon D, Montrose DM, Miewald J, Gur RE, Gur RC, et al. Social cognition deficits among individuals at familial high risk for schizophrenia. Schizophr Bull 2009 In press.
23. Cho RY, Ford JM, Krystal JH, Laruelle M, Cuthbert B, Carter CS. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia. Schizophr Bull 2005;31:865-869
24. Trivedi JK. Cognitive deficits in psychiatric disorders: Current status. Indian J Psychiatry 2006;48:10-20.
25. Harvey PD, Keefe RS. Improvement in cognition with atypical antipsychotics: Summary of twenty studies. Am J Psychiatry 2001;158:176-184
26. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
27. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 1999;25:201-202
28. Hellewell JS. The effect of quetiapine in improving cognitive impairment in schizophrenia. Eur Neuropsychopharmacol 2000;10:300-301
29. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in nevermedicated first-episode psychotic and medicated chronic schizophrenic patients: Possible implications for treatment outcome. Schizophr Res 2003;60:117-123
30. Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006;82:95-106.
31. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-647
32. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double blind 52-week comparison. Am J Psychiatry 2007;164:1061-1071
33. Green MF. Cognition, drug treatment, and functional outcome in schizophrenia: A tale of two transitions. Am J Psychiatry 2007;164:992-994
34. Sumiyoshi T. Possible dose-side effect relationship of antipsychotic drugs: Relevance to cognitive function in schizophrenia. Expert Rev Clin Pharmacol 2008;1:791-802.
35. Chung YC, Lee CR, Park TW, Yang KH, Kim KW. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial. World J Biol Psychiatry 2009;10:156-162
36. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71:138-149
37. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-1130